Targeted therapy, as a new therapeutic method, plays an important role in the treatment of ESCC (32), such as targeting the metabolic vulnerability of SLC7A11-high cancer cells, glucose transporter type 1 biosynthesis, and glutathione induces NADPH dissipation, significant disulfide molecules accumulation, such as cysteine, and ROS accumulation, thereby inhibiting tumor growth and spread (33, 34). This evidence concerns the gene SLC7A11 and neoplasm.